A Safety Study of Oral ZSTK474 in Patients With Cancer
Phase: Phase 1
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT01280487
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-110
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.
Dana-Farber Cancer Institute
Geoffrey Shapiro, MD, PhD,
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute:
Andrew Wolanski, 617-632-6623,
1. Male or females ≥18 years of age;
2. Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for
which available therapy is not effective;
3. ECOG performance status score of ≤2 and an expected survival of >8 weeks;
4. Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer
therapies; all toxicities must be determined to be below Grade 2 (assessed using the
NCI CTCAE v4.0).
5. Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil
count (ANC) >1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);
6. Subjects who are willing and able to provide written informed consent.
In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory
biopsies of tumor tissue twice during the first cycle (before and during dosing) and must
have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or
percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.
1. Women who are pregnant or breastfeeding;
2. Men or women of reproductive potential who are not willing to use acceptable means of
contraception while on study drug and for an additional 90 days after the last dose
of study drug;
3. Body Mass Index (BMI) is ≥30 kg/m2;
4. Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS
metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled
(i.e., if CNS lesions have been stable in size for at least one month and the subject
is off steroid and anti-convulsants).
5. Have received any investigational interventional agents within the 4 weeks prior to
the start of dosing with ZSTK474;
6. Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or
have received any of these non-investigational agents within the previous 4 weeks or
5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;
7. Are not able or willing to comply with the study procedures, including the study
8. Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;
9. Have serious or significant intercurrent illnesses or underlying diseases, such as:
2. Gastrointestinal disorder
3. Hepatic: AST or ALT >2.5 x ULN (or >5.0 x ULN with liver metastases) or serum
bilirubin >1.5 x ULN;
4. Renal (acute or chronic renal disease or eGFR <55 mL/min)
- Uncontrolled hypertension or blood pressure >140/90 mmHg;
- Symptomatic congestive heart failure;
- Myocardial infarction within the past 6 months;
- Unstable angina pectoris;
- Cardiac arrhythmia;
- Congenital long QT syndrome;
- QTc >450 msec for men or >470 msec for women.
- Known diagnosis of HIV infection;
- Other ongoing or active infections;
- Psychiatric illness, substance abuse or social situation that would
preclude study compliance.
- Other serious concurrent illness that would preclude assessment of drug
- PT/PTT)/APTT/INR >ULN for subjects not on anti-coagulants; INR > 1.5 x ULN
for subjects on low dose warfarin.
10. Current treatment with the following drugs:
- any anti-seizure medications;
- therapeutic anti-coagulant doses of warfarin.